Arene oxide metabolites of aromatic anticonvulsants (phenytoin, phenobarbital, and carbamazepine) may be involved in the pathogenesis of hypersensitivity reactions. We investigated 53 patients with clinical sensitivity to anticonvulsants by exposing their lymphocytes in vitro to drug metabolites generated by a murine hepatic microsomal system. The diagnosis of a hypersensitivity reaction was corroborated by in vitro rechallenge for each drug (phenytoin, n = 34; phenobarbital, n = 22; carbamazepine, n = 25) when cytotoxicity (% dead cells) exceeded 3 SD above the mean result for controls. Cross-reactivity among the drugs was noted. 7 out of 10 patients who had received all three anticonvulsants had adverse reactions to each. 40 out of 50 patients tested to all three drugs in vitro were positive to each. Adverse reactions were indistinguishable among anticonvulsants. Skin rash (87%), fever (94%), hepatitis (51%), and hematologic abnormalities (51%) were common clinical features of each drug. 62% of reactions involved more than two organs. Cells from patients' parents exhibited in vitro toxicity that was intermediate between values for controls and patients. In vitro testing can help diagnose hypersensitivity to anticonvulsants. Cells from patients may also be used for prospective individualization of therapy to decrease risk of adverse reaction. Cross-reactivity among the major anticonvulsants is common and should be considered before deciding on alternative therapy.
Introduction
The anticonvulsant effect of phenytoin was described by Merritt and Putnam in 1938 (1) . In their review oftoxic symptoms of therapy, two cutaneous reactions were identified (2) . The first was a mild, morbilliform eruption that cleared up when the drug was stopped and often did not recur when therapy was reinstituted. This was a common side-effect (5% of patients), which now is believed to be dose related, but the exact pathogenesis remains unknown (3) . The second was a severe, exfoliative dermatitis that was associated with fever and eosin-ophilia in < 1% of their patients. The systemic nature of this rarer complication was described 11 years later (4) .
Unwelcome hypersensitivity reactions have been described for other established drugs (e.g., sulfonamides) and have been responsible for the demise of otherwise promising therapeutic agents (e.g., ticrynafen and zomepirac). This could not have been predicted by existing animal models, nor by the monitoring of serum drug concentrations.
Furthermore, such adverse events are rare and the possibility that a drug may cause hypersensitivity reactions can be missed during early human exposures. The low reaction rate suggests that a subpopulation may be at risk of developing idiosyncratic toxicity and that this might be secondary to a genetic defect of drug metabolism. We have undertaken the study of aromatic anticonvulsants as a model to help understand the pathogenesis and genetics of idiosyncratic reactions and to develop approaches to diagnosis and prediction.
Hypersensitivity reactions, as defined in this context, are characteristically rare (1:10,000 exposures), are delayed in onset after initiation of drug therapy, and can cause severe morbidity or result in death. The "phenytoin reaction" is described as a febrile illness associated with skin rash, lymphadenopathy, possible hepatitis, nephritis, pneumonitis, or hematologic abnormalities (5-1 1). In 1953 McGeachy and Bloomer described an identical syndrome secondary to phenobarbital ( 12). Their three patients had severe (two were fatal) reactions to therapeutic doses of phenobarbital characterized by fever, delirium, exfoliative dermatitis, hepatitis, and nephritis. Hepatitis secondary to phenobarbital is not discussed in standard reference texts but has been well described in at least nine cases (13) . Carbamazepine hypersensitivity has also been reported with skin rash (including toxic epidermal necrolysis), fever, hepatitis, bone marrow toxicity, pneumonitis, and pseudolymphoma (14) (15) (16) (17) (18) .
Problems with both diagnosis and prediction may arise when anticonvulsant toxicity occurs. Diagnostic confusion can occur with infection, collagen vascular disease, or lymphoma (19) . Also, if a patient is being treated with more than one anticonvulsant it is difficult to differentiate which drug may be responsible for the reaction, and diagnostic rechallenge may result in severe reactions in the truly drug-sensitive patient. Potential cross-reactivity among the three major anticonvulsants limits the choices for future therapy in a patient who has had a reaction (20, 21) .
Phenytoin, phenobarbital, and carbamazepine are metabolized to hydroxylated aromatic compounds. This would suggest that arene oxides are intermediates in the reaction, the result of oxidative (cytochrome P-450) metabolism ( Fig. 1 ) (22, 23 ies have suggested that abnormal detoxification ofarene oxides might predispose patients to toxicity from phenytoin and similar compounds (1 1, 25-27) . A cellular model is necessary to investigate the pathogenesis of anticonvulsant hypersensitivity reactions and genetic defects in detoxification. The metabolic pathway is modeled in vitro by exposing peripheral blood lymphocytes to metabolites generated by a source of cytochrome P-450 (a mouse hepatic microsomal system). Lymphocytes are chosen, not as immunologic cells, but as easily obtained cells that contain epoxide hydrolases, enzymes involved in arene oxide detoxification. An in vitro cellular model allows safe rechallenge for the confirmation of drug sensitivity and the prediction of future toxicity risk of old and new anticonvulsants.
Methods
Subjects. Control subjects included 49 normal volunteers (aged 20-45 yr) never exposed to anticonvulsants and 10 patients (aged 20-35 yr) with seizure disorders who were chronically treated with phenytoin without adverse reactions.
Patients. 53 patients with suspected hypersensitivity reactions were studied by the in vitro lymphocyte toxicity assay, including three patients with phenytoin hepatotoxicity and one patient with anticonvulsant-induced aplastic anemia previously reported (11, 26). Patients were referred to us for diagnostic confirmation ofa drug-induced reaction and/or to assist in the choice of future therapy. When possible, the parents and siblings of patients were studied.
In vitro lymphocyte toxicity assay. The in vitro assay for drug-metabolite-induced toxicity has been previously reported in detail (25, 28 Statistical analysis. Each experimental condition (no drug, phenytoin, phenobarbital, and carbamazepine) was studied in triplicate samples and the mean percent of dead lymphocytes was determined. The coefficient of variation was < 10% for all experiments. The change from baseline values (calculated as percent dead cells in the presence of drug minus the percent dead cells in the absence of drug) was used as the measure oftoxicity. Toxicity values from patients and relatives that were above the upper limit for normals (a + 3 SD) were considered positive. Differences among groups were determined by the use of confidence intervals, analysis of variance, and Duncan multiple range test.
Results
Clinical features of patients (Table I ). The age range in the patients studied was from 1 to 76 yr. 33 patients were younger than 18 yr (20 male, 13 female) and 20 were adults (9 male, 11 female).
The clinical presentation of a typical reaction was with the onset of fever a mean of 21 d (range 7 Target organ involvement during the first reaction to an anticonvulsant. * Abbreviations in the anticonvulsant therapy. This was followed by the development necrolysis. Manifestations of internal organ involvement of a skin rash (87% of patients) that varied in severity from a tended to be subsequent to this, most commonly hepatitis faint generalized exanthematous eruption to toxic epidermal (5 1 %) and nephritis ( 1%). Multi-organ involvement (i.e., two or more major organs involved, not including eosinophilia, atypical lymphocytosis, and fever) was noted in 31 patients. Of the remaining 22 patients, 20 had skin rash alone. When present, atypical lymphocytosis occurred in the first week of the reaction and eosinophilia was noted by the second week. Arthralgia and arthritis were notably absent in our series. In some patients, despite discontinuation of anticonvulsant therapy at the onset of a reaction, manifestations of toxicity occurred in previously uninvolved organs, or increased in organs already involved.
In vitro toxicity assay. In the absence of microsomes or the NADPH-generating system phenytoin, phenobarbital, or carbamazepine are not toxic to cells from controls or patients.
Toxicity of the anticonvulsant metabolites to cells from controls is shown in Table II . There was no difference between normals and patients who could tolerate phenytoin. Toxicity of the metabolites to cells from patients with a clinical history suggestive of a hypersensitivity reaction differ significantly from controls (P < 0.001) (Table II) .
Family studies. Toxicity of phenytoin-metabolites to cells from controls, patients who had sustained hypersensitivity reactions to phenytoin, and the parents of seven ofthose patients is shown in a histogram (Fig. 2) . The three populations are statistically distinct (P < 0.001). The parent (intermediate) group has a mean of 5.6% dead cells above baseline (±0.3 SEM).
The results from two families are shown in Fig. 3 . Two siblings in the first family (subjects 5 Lymphocytes from 50 patients were tested to all three anticonvulsants. 40 patients (80%) were sensitive in vitro to all three drugs, 4 were sensitive to a single drug (phenytoin = 2, carbamazepine = 2), and 6 were sensitive to two drugs.
One patient (patient 18) had had clinical reactions to phenytoin and carbamazepine (1 1). In vitro testing suggested phenobarbital would be safe, and the patient ultimately tolerated this medication. One patient (patient 26) had an adverse reaction to phenytoin (26) , and, as predicted by in vitro testing, could tolerate both phenobarbital and carbamazepine. Clinical DPH* 1
In vitro DPH Patient 20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38 Clinical DPH 0
In Cross-reactivity among the anticonvulsants was demonstrated both in vivo and in vitro. A structural alteration in an epoxide hydrolase could be responsible for these observations. Heterogeneous enzymatic defects may explain the subsets of patients who are intolerant to all, or to only one or two, of the anticonvulsants. Similar pharmacogenetic variation in substrate specificity has been demonstrated for other drug metabolizing enzymes, such as N-acetyl transferase and debrisoquine P-450 (30) . Patients who have sustained hypersensitivity reactions to anticonvulsants are at high risk of reacting to the other usual drugs of choice. In light of this, the benefits of further therapy must be considered very carefully. Among our patients who needed anticonvulsants, all were able to tolerate valproic acid, but this was not always appropriate for seizure control.
We have previously shown that people sensitive to sulfonamides may have a defect in detoxification by glutathione transferases (31). The cells from these patients have apparently normal expoxide hydrolases, and cross-reactivity between the anticonvulsants and sulfonamides has not been seen.
The type of reaction seen in this study has historically been called a "hypersensitivity syndrome." This terminology is unfortunately very nonspecific and might be appropriate for a wide variety of unpredictable or immunologically mediated, drug-induced diseases. Park and his colleagues discuss the complexity of the pathophysiology of drug hypersensitivity in their review (24) . The syndrome described in this paper might best be recognized as a reaction pattern with varying manifestations in response to a variety of drugs. The same pattern is not well described for nondrug etiologies and no disease-related descriptive term exists. Better nomenclature should unfold as the pathogenesis of all hypersensitivity reactions is uncovered. In the meantime we will continue to refer to the delayed, febrile, multiorgan toxicity seen here as the "anticonvulsant hypersensitivity syndrome."
The in vitro lymphocyte toxicity assay provides a model for the investigation of some hypersensitivity reactions. Our work suggests that it may aid in diagnosis and in the prediction of adverse reactions. When a simpler assay can become widely available, it would provide a rational, cost-effective approach to screening patients who are to receive anticonvulsants. For patients who are sensitive to all three aromatic anticonvulsants, an in vitro test can be used to aid the development of potentially safer new compounds. Further work needs to be done to determine the enzyme defect responsible for the limited detoxification capacity. Analogues of the major anticonvulsants could be developed for these patients and safety assessed in vitro, before in vivo challenge (i.e., therapy).
